News | August 24, 2023
Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ
The company has entered into a three-year Deferred Prosecution Agreement
The company has entered into a three-year Deferred Prosecution Agreement
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
The agreement is for USFDA approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
